Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2016-01-01
|
| Col·lecció: | Case Reports in Oncological Medicine |
| Accés en línia: | http://dx.doi.org/10.1155/2016/2490168 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|